  |
 | Up a level |
Han, HS and Diéras, V and Robson, ME and Palácová, M and Marcom, PK and Jager, A and Bondarenko, I and Citrin, D and Campone, M and Telli, ML and Domchek, SM and Friedlander, M and Kaufman, B and Ratajczak, C and Coates, A and Bonnet, P and Qin, Q and Qian, J and Giranda, VL and Shepherd, SP and Isakoff, SJ and Puhalla, S (2017) Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study. Cancer Research, 77 (4Suppl). P.-S2-05. ISSN 0008-5472 (Print), 1538-7445 (Online)
Diéras, V and Han, HS and Robson, ME and Palácová, M and Marcom, PK and Jager, A and Bondarenko, I and Citrin, D and Campone, M and Telli, ML and Domche, SM and Friedlander, M and Kaufman, B and Ratajczak, C and Coates, A and Bonnet, P and Qin, Q and Qian, J and Giranda, VL and Shepherd, SP and Puhalla, S and Isakoff, SJ (2017) Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. Cancer Research, 77 (4 Supp). P42202-P42202. ISSN 0008-5472 (Print), 1538-7445 (Online)
